Clinical Trial Search

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis) — 4.7; -53.5; -51.7 percent change — p=<0.0001

Primary: Proportion of Patients With Adenocarcinoma Achieving a Pathologic Complete Response (CR) After Surgery — 19 percentage of participants

Primary: Time-weighted Summed Pain Intensity Difference (SPID) Over the 12-hour Study Period (SPID12). — 36.04 units on a scale

Primary: Area Under the Concentration-time Curve of BI 113608 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 494; 1840; 1320…

Primary: Mean Percent Change in Inflammatory, Non-inflammatory and Total Lesion Counts From Baseline to Week 8. — -78.70; -61.52; -69.32; -77.09 Percent change — p=0.0769

Primary: Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 90 — -7.69; -7.22; -7.59; -8.54 Units on a scale — p=<0.0001

Primary: Increased Radioiodine Uptake — 6 Participants

Primary: T Cell Activation — 1.8; 1.3 percentage of CD4+ T cells

Primary: Mean Change From Baseline in the Total Nasal Sym. Score (TNSS) at Post-NAC 15 Minutes (Min) — 3.8; 5.9 Score on a scale

Primary: Development of de Novo Hepatitis B Infection After Transplant With a Core Antibody Positive Liver — 5 Participants

Primary: Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma — 61; 45; 54 percentage of participants

Primary: Treatment Success Defined as Resolution of Fever by 24 Hours Postpartum — 43; 49 Participants — p=1.0

Primary: Change From Baseline in Patient-Reported Eye Dryness Score to Day 84 — 69.0; 68.3; -30.7; -37.9 units on a scale — p==0.0007

Primary: Systolic Blood Pressure — 128.99; 131.4; 131.21; 127.45 mm Hg

Primary: Response Rate — 20 percentage of participants